Story
Capital Bancorp Stock Soars on $728 Million Acquisition by Peoples Bancorp

Summary
Shares of Capital Bancorp surged to a 52-week high after Peoples Bancorp announced it would acquire the regional bank in an all-stock transaction valued at approximately $728 million.
Shares of Capital Bancorp (CBNK) surged more than 11% in afternoon trading after Peoples Bancorp announced an agreement to acquire the Maryland-based bank in an all-stock deal. The transaction values Capital Bancorp at approximately $728 million.
Transaction Details
Under the terms of the merger agreement, shareholders of Capital Bancorp will receive 1.11 shares of Peoples Bancorp common stock for each share of Capital they own. This exchange ratio implies a value of $43.75 per share for Capital Bancorp, representing a significant premium over its previous closing price.
The deal, which is expected to close in the first half of 2027, will create a combined banking entity with significant scale. The new institution is projected to hold approximately:
- $14 billion in total assets
- $10 billion in loans
- Over 150 branch locations across eight states and Washington, D.C.
Market Reaction
AdThe acquisition announcement sent Capital Bancorp's stock to a new 52-week high of $40.26. Trading volume in CBNK was more than five times its daily average, indicating heavy activity from investors, including those engaged in merger arbitrage.
The stock's strong performance was also supported by a favorable macroeconomic environment. A softer-than-expected August PCE inflation report, the Federal Reserve's preferred inflation gauge, eased investor concerns about a potential near-term interest rate hike, providing a constructive backdrop for financial stocks.
Additional Scrutiny
The transaction has drawn the attention of an investor rights law firm, which separately announced it is investigating whether Capital Bancorp's board secured the best possible price for its shareholders. This adds a layer of scrutiny to the deal as it moves toward completion.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.

Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.